General Info

Celsus, Inc, a closely-held enterprise, was founded in 1987 to manufacture derivatives of crude heparin and to pursue the development of related complex carbohydrates belonging to the family of sulfated glycosaminoglycans for unmet medical and biomedical needs. The Company's tradename evokes the name of Aulus Cornelius Celsus, a first-century Roman medical encyclopedist.Celsus Laboratories, Inc, a wholly-owned subsidiary company located in Cincinnati, is a USDA-approved, FDA-registered drug establishment that manufactures bulk-lyophilized heparin sodium of porcine tissue and various derivatives thereof.Celsus Biopharmaceuticals, Inc, a wholly-owned subsidiary company, was founded in 1995 to develop a proprietary inhibitor of clot-bound thrombin and heparin cofactor II agonist. Its improved pharmacological profile makes it a preferable alternative to heparin in a variety of venous and arterial thrombo-embolic disorders, including states of heparin resistance and heparin-induced thrombocytopenia ( HIT ) where heparins are contraindicated.Celsus BioMedical B.V., a wholly-owned subsidiary of Celsus, Inc located in Maastricht was founded in 2008 to exploit new business opportunities in Europe and the Middle East.Celsus-Biomat B.V., an affiliated company of Celsus BioMedical B.V., located in Geleen the Netherlands, was founded in 2008 to manufacture and distribute bioactive polymers.1988 - introduction of a bulk-lyophilized Heparin Sodium USP 1989 - introduction of Heparin Lithium meeting NCCLS specifications1990 - introduction of Heparin Ammonium and Heparin Calcium USP 1991 - completion of phase I clinical studies of ardeparin sodium2005 - first to discover an anticoagulant / antagonist of heparin-induced-thrombocytopenia 2006 - validation of a PCR method to determine animal origin by specie